These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31362682)

  • 1. Aligned Expression of IFI16 and STING Genes in RRMS Patients' Blood.
    Helbi S; Ravanbakhsh B; Karimi M; Kooti W; Jivad N
    Endocr Metab Immune Disord Drug Targets; 2020; 20(6):878-886. PubMed ID: 31362682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B Virus Might Be Sensed by STING-Dependent DNA Sensors and Attenuates the Response of STING-Dependent DNA Sensing Pathway in Humans with Acute and Chronic Hepatitis B Virus Infection.
    Chen H; He G; Chen Y; Zhang X
    Viral Immunol; 2020 Dec; 33(10):642-651. PubMed ID: 33170089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta.
    Mazdeh M; Moradi N; Khoshroo E; Shayesteh Z; Taheri M; Sayad A; Omrani MD; Hajilooi M; Roshanaei G; Solgi G
    J Neuroimmunol; 2018 Jan; 314():24-29. PubMed ID: 29157944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
    van Baarsen LG; Vosslamber S; Tijssen M; Baggen JM; van der Voort LF; Killestein J; van der Pouw Kraan TC; Polman CH; Verweij CL
    PLoS One; 2008 Apr; 3(4):e1927. PubMed ID: 18382694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy.
    Taheri M; Mirinezhad M; Omrani MD; Sajjadi E; Inoko H; Sayad A
    Iran J Allergy Asthma Immunol; 2017 Feb; 16(1):21-27. PubMed ID: 28417621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The STING-IFN-β-Dependent Axis Is Markedly Low in Patients with Relapsing-Remitting Multiple Sclerosis.
    Masanneck L; Eichler S; Vogelsang A; Korsen M; Wiendl H; Budde T; Meuth SG
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis.
    Liguori M; Fera F; Patitucci A; Manna I; Condino F; Valentino P; Telarico P; Cerasa A; Gioia MC; di Palma G; Quattrone A
    Brain Res; 2009 Feb; 1256():123-8. PubMed ID: 19071096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFI16 is required for DNA sensing in human macrophages by promoting production and function of cGAMP.
    Jønsson KL; Laustsen A; Krapp C; Skipper KA; Thavachelvam K; Hotter D; Egedal JH; Kjolby M; Mohammadi P; Prabakaran T; Sørensen LK; Sun C; Jensen SB; Holm CK; Lebbink RJ; Johannsen M; Nyegaard M; Mikkelsen JG; Kirchhoff F; Paludan SR; Jakobsen MR
    Nat Commun; 2017 Feb; 8():14391. PubMed ID: 28186168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. History of modern multiple sclerosis therapy.
    Lublin F
    J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a negative feedback loop between cyclic di-GMP-induced levels of IFI16 and p202 cytosolic DNA sensors and STING.
    Panchanathan R; Liu H; Xin D; Choubey D
    Innate Immun; 2014 Oct; 20(7):751-9. PubMed ID: 24131791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of interferon β-1a and interferon β-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: a 3-year longitudinal study.
    Stępień A; Chalimoniuk M; Lubina-Dąbrowska N; Chrapusta SJ; Galbo H; Langfort J
    Neuroimmunomodulation; 2013; 20(4):213-22. PubMed ID: 23711618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon γ-inducible protein (IFI) 16 transcriptionally regulates type i interferons and other interferon-stimulated genes and controls the interferon response to both DNA and RNA viruses.
    Thompson MR; Sharma S; Atianand M; Jensen SB; Carpenter S; Knipe DM; Fitzgerald KA; Kurt-Jones EA
    J Biol Chem; 2014 Aug; 289(34):23568-81. PubMed ID: 25002588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STING-Mediated IFI16 Degradation Negatively Controls Type I Interferon Production.
    Li D; Wu R; Guo W; Xie L; Qiao Z; Chen S; Zhu J; Huang C; Huang J; Chen B; Qin Y; Xu F; Ma F
    Cell Rep; 2019 Oct; 29(5):1249-1260.e4. PubMed ID: 31665637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleosomal dsDNA Stimulates APOL1 Expression in Human Cultured Podocytes by Activating the cGAS/IFI16-STING Signaling Pathway.
    Davis SE; Khatua AK; Popik W
    Sci Rep; 2019 Oct; 9(1):15485. PubMed ID: 31664093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OAS1: a multiple sclerosis susceptibility gene that influences disease severity.
    O'Brien M; Lonergan R; Costelloe L; O'Rourke K; Fletcher JM; Kinsella K; Sweeney C; Antonelli G; Mills KH; O'Farrelly C; Hutchinson M; Tubridy N
    Neurology; 2010 Aug; 75(5):411-8. PubMed ID: 20679634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.